Overview

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
Phase:
PHASE2
Details
Lead Sponsor:
VSPharmTech Co.,Ltd.
Treatments:
Cisplatin
Radiation